Oxacell

Oxacell AG is a private, clinical-stage biotech based in Potsdam/Munich, Germany, specializing in advanced therapy medicinal products (ATMPs) using adipose-derived mesenchymal stem cells. The company operates a GMP-certified manufacturing platform and is developing both autologous and allogeneic cell therapies targeting orthopedic, autoimmune, and liver diseases. While likely pre-revenue from product sales, its strategy involves certified collection centers, academic partnerships, and a pipeline progressing through clinical development and regulatory pathways.

Proprietary GMP platform for extraction, cultivation, and banking of highly potent mesenchymal stem cells (MSCs) from adipose tissue, supporting both autologous and allogeneic therapy production.

Competition is intense from numerous biotech firms and academic centers developing MSC therapies for similar indications. Larger pharmaceutical companies are also active in cell therapy through partnerships and acquisitions. Oxacell must differentiate on the potency of its adipose-derived cells, its proprietary extraction process, and clinical data.